利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

685 条记录 (耗时 0.02 秒)

    VECTORS FOR HIV-1 VACCINE
    52.
    发明申请
    VECTORS FOR HIV-1 VACCINE 审中-公开
    HIV-1疫苗的载体

    公开(公告)号：WO2008151633A2

    公开(公告)日：2008-12-18

    申请号：PCT/DK2008000217

    申请日：2008-06-13

    申请人： SKAU APS ,  TOLSTRUP MARTIN ,  PEDERSEN FINN SKOU ,  OESTERGAARD LARS ,  DUCH MOGENS RYTTERGAARD ,  NIELSEN TEA KIRKEGAARD

    发明人： TOLSTRUP MARTIN ,  PEDERSEN FINN SKOU ,  OESTERGAARD LARS ,  DUCH MOGENS RYTTERGAARD ,  NIELSEN TEA KIRKEGAARD

    IPC分类号： C12N15/09

    CPC分类号： C12N15/86 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  A61K2039/53 ,  C07K14/005 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16322 ,  C12N2740/16334 ,  C12N2810/50 ,  C12N2810/6054 ,  C12N2830/15 ,  C12N2830/60 ,  C12N2840/206

    摘要： The invention provides a lentiviral envelope polypeptide or a nucleic acid sequence encoding a lentiviral envelope polypeptide, which are capable of inducing an immunogenic response against lentiviral infection, such as HIV infection. Examples of envelopes are HIV-1, HIV-2 or SIV envelope proteins or variants thereof. A specific such envelope variant is devoid of its C-terminal domain. The lentiviral envelope polypeptide or nucleic acid encoding said polypeptide is provided in vectors, methods, proviruses, retroviral particles, uses, compositions, vaccines, vaccine compositions and kits. Moreover, the lentiviral envelope polypeptide or nucleic acid encoding said polypeptide may be provided in combination with other compounds, such as selective marker genes, adjuvants, and immunomodulating agents. The invention is applicable for generation of retroviral particles for specific targeting of host cells. The retroviral particles may be used for integration of trangenes in host cells and induction of an immunogenic response, for example against HIV-1.

    摘要翻译： 本发明提供了慢病毒包膜多肽或编码慢病毒包膜多肽的核酸序列，其能够诱导针对慢病毒感染（例如HIV感染）的免疫原性应答。 信封的实例是HIV-1，HIV-2或SIV包膜蛋白或其变体。 特定的这种信封变体没有其C末端结构域。 载体，方法，前病毒，逆转录病毒颗粒，用途，组合物，疫苗，疫苗组合物和试剂盒中提供了编码所述多肽的慢病毒包膜多肽或核酸。 此外，编码所述多肽的慢病毒包膜多肽或核酸可以与其它化合物如选择性标记基因，佐剂和免疫调节剂组合提供。 本发明可用于产生用于特异性靶向宿主细胞的逆转录病毒颗粒。 逆转录病毒颗粒可用于将宿主细胞中的转基因整合并诱导免疫原性应答，例如针对HIV-1。

    IMMUNOSTIMULATORY COMBINATIONS FOR VACCINE ADJUVANTS
    56.
    发明申请
    IMMUNOSTIMULATORY COMBINATIONS FOR VACCINE ADJUVANTS 审中-公开
    疫苗补充剂的免疫组化联合

    公开(公告)号：WO2007120368A3

    公开(公告)日：2008-06-12

    申请号：PCT/US2007000616

    申请日：2007-01-09

    申请人： UNIV CALIFORNIA ,  KORNBLUTH RICHARD SYD ,  STONE GEOFFREY WILLIAM

    发明人： KORNBLUTH RICHARD SYD ,  STONE GEOFFREY WILLIAM

    IPC分类号： C12P21/02 ,  C07H21/04 ,  C07K14/25 ,  C12N1/21

    CPC分类号： A61K39/21 ,  A61K38/191 ,  A61K39/12 ,  A61K2039/5152 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  C12N2740/16134 ,  C12N2740/16234 ,  A61K2300/00

    摘要： This invention discloses immunostimulatory combinations of Tumor Necrosis Factor Receptor Superfamily (TNFRSF) agonists, Toll-Like Receptor (TLR) agonists, "domain present in NAIP,CIITA, HET-E, TP-I (NACHT)-Leucine Rich Repeat (LRR)" or "NLR" agonists, RIG-I-Like Helicase or "RLH" agonists, purinergic receptor agonists and cytokine/chemokine receptor agonists, together with delivery methods. The combinations, when used alone at the site of pathology, provide immunostimulation that induces host humoral and cellular immunologic responses to eliminate pathogens or neoplasms. Alternatively, when the combinations are used with a defined antigens, these combinations can induce focused humoral and cellular immunologic responses useful as prophylactic and/or ameliorative therapeutic modalities for infections and the treatment of neoplastic disorders.

    摘要翻译： 本发明公开了肿瘤坏死因子受体超家族（TNFRSF）激动剂，Toll样受体（TLR）激动剂，“NAIP，CIITA，HET-E，TP-1（NACHT）-Lucucine Rich Repeat（LRR）”中存在的结构域的免疫刺激组合 “或”NLR“激动剂，RIG-I型Helicase或”RLH“激动剂，嘌呤能受体激动剂和细胞因子/趋化因子受体激动剂，以及递送方法。 当在病理部位单独使用时，组合提供诱导主体体液和细胞免疫应答以消除病原体或肿瘤的免疫刺激。 或者，当组合与定义的抗原一起使用时，这些组合可以诱导用作感染的预防和/或改善治疗方式的集中的体液和细胞免疫应答以及肿瘤性疾病的治疗。

    IMPROVED VACCINES AND METHODS FOR USING THE SAME
    59.
    发明申请
    IMPROVED VACCINES AND METHODS FOR USING THE SAME 审中-公开
    改进的疫苗和使用该疫苗的方法

    公开(公告)号：WO2008014521A2

    公开(公告)日：2008-01-31

    申请号：PCT/US2007/074769

    申请日：2007-07-30

    申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  WEINER, David, B. ,  YAN, Jian

    发明人： WEINER, David, B. ,  YAN, Jian

    IPC分类号： A61K39/21

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55538 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16322 ,  C12N2740/16334 ,  C12N2760/16134 ,  C12N2770/24234

    摘要： Improved anti-HlV immυnogens and nucleic acid molecules that encode them are disclosed, lmmunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HlV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed. Pharmaceutical composition, recombinant vaccines comprising and live attenuated pathogens are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.

    摘要翻译： 公开了改进的抗-HIV免疫原和编码它们的核酸分子，公开的免疫原包括那些具有针对HIV亚型A包膜蛋白的共有序列的那些，具有针对H1V亚型B包膜蛋白的共有序列的那些， HIV亚型C包膜蛋白的共有序列，具有HIV亚型D包膜蛋白的共有序列的那些序列，具有HIV亚型B共有Nef-Rev蛋白的共有序列的序列，以及具有共有序列的那些序列形成HIV Gag蛋白亚型A，B，C和 D.改进的抗HPV免疫原和编码它们的核酸分子; 改进的抗HCV免疫原和编码它们的核酸分子; 改进的hTERT免疫原和编码它们的核酸分子; 并公开了改进的抗流感免疫原和编码它们的核酸分子。 公开了药物组合物，包含和减毒活病原体的重组疫苗以及在个体中诱导针对HIV，HPV，HCV，hTERT和流感的免疫应答的方法。